GlassScriptPhysician profile
Russell C Langan
NPI 1063646313
$9,270.33
in general payments reported to CMS, 2019-2025
13 companies · $6,678 in 2025
The $6,678 reported for 2025 was more than what 91% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.10 · 2020: $38.76 · 2021: $54.13 · 2023: $142 · 2024: $2,289 · 2025: $6,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,383 · Consulting Fee: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,383.34 |
| Consulting Fee | $1,725.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $7,124.99 | 2024-2025 | Hemoblast Bellows |
| Ethicon US, LLC | $1,729.72 | 2025 | Echelon Flex, Enseal |
| Genentech USA, INC. | $142.13 | 2023 | |
| Intuitive Surgical, INC. | $54.13 | 2021 | |
| Intera Oncology, INC | $36.70 | 2024 | Intera |
| Acera Surgical, INC. | $33.20 | 2025 | Restrata Wound Matrix |
| Csl Behring | $28.29 | 2019 | |
| Merck Sharp & Dohme LLC | $25.95 | 2019 | |
| Boston Scientific Corporation | $23.83 | 2020 | |
| Molnlycke Health Care US, LLC | $20.86 | 2025 | Mepilex Border Post-Op Ag, Mepitel One, Mepilex Border Post-Op |
| Mimedx Group, INC. | $20.74 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $14.93 | 2020 | |
| Abbvie INC. | $14.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Langan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.